Saltar para
Menu principal :
Submenu :
Designações Órfãs por área geográfica
- Ma09-Hrpe Cells
- Macitentan
- Maleato de Nimorazol
- Mammalian target of rapamcyin (mTOR) inhibitor
- (manganese, dichloro [(4aR, 13aR, 17aR, 21aR)-1, 2, 3, 4, ...tetraazacycloheptadecine-kN5, kN13, kN18, kN21, kN22]-)
- Mannitolum
- Maribavir
- Mavoglurant
- Maytansinoid-conjugated human monoclonal antibody against mesothelin
- Mecasermin
- Mecasermin rinfabate
- Melarsoprol
- Melatonina
- Melfalam
- Meloxicam
- Mepolizumab
- Mercaptopurina (suspensão oral)
- Mercaptopurine (oral liquid)
- Mesilato de imatinib
- Mesilato de masitinib
- Mesilato de nafamostato
- Metastable technetium 99 [99mTc] Demogastrin 2
- Methotrexate (oral liquid)
- Methoxsalen
- Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate
- Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-[-----]-D-glucopyranoside 2,6-bis(hydrogen sulfate) octasodium salt
- Metiltionina
- Metotrexato
- Metreleptin
- Metronidazole
- Mibefradil
- Microvesícula multilamelar composta por fosfatidilcolina, esfingomielinas, fosfatidiletanolamina, fosfatidilserina, fosfatidilinositol e colesterol
- Midodrine hydrochloride
- Midostaurina
- Mifamurtide
- Mifepristone
- Migalastat hydrochloride
- Milatuzumab
- Milciclib maleate
- Miltefosine
- Minicorpo recombinante de origem humana anti- componente C5 do complemento fundido com o motivo RGD
- Minicorpo recombinante de origem humana contra o componente C5 do complemento
- Mitotane
- Mitoxantrona
- Mixture of two allogeneic human pancreatic cancer cell lines stably transduced with a retroviral vector encoding the murine alpha-(1,3)-galactosyltransferase gene
- Modafinil
- Modified recombinant human C-type natriuretic peptide
- Mogamulizumab
- Monarsen
- Moroctocog alpha
- Mycobacterium vaccae inactivada pelo calor (célula completa)
- Mycophenolate mofetil
